Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world multicenter study of camrelizumab-based cross-line therapy after first-line camrelizumab plus chemotherapy failure in metastatic NSCLC
ChiCTR2200058209Phase 4Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (4 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Overall survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2200058209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058209.